iGeneTech Bioscience Co., Ltd.
EN

iGeneTech focuses on respiratory syndrome panels, with 150,000 probes enabling rapid identification of multiple pathogens

Table of Content [Hide]

    Affected by abrupt temperature changes and environmental factors in autumn and winter, individuals often experience upper respiratory tract-related symptoms such as fever, cough, nasal congestion, and sore throat. When multiple symptoms occur concurrently, they are collectively referred to in medicine as "respiratory syndrome."

    The core cause of its onset is closely related to the impaired defense function of the respiratory mucosa. The main factor lies in the invasion of the respiratory tract by pathogens such as viruses, bacteria, mycoplasma, and chlamydia during the high-incidence period of infections. These pathogens adhere to mucosal epithelial cells, triggering local inflammatory responses, which in turn lead to symptoms like cough and sputum production. High-risk groups include immunocompromised individuals, people with allergic constitutions, those with long-term exposure to high-risk environments, and individuals with poor living habits.

    For respiratory syndrome caused by infectious factors, the primary transmission route is droplet transmission, and its clinical manifestations include upper respiratory tract infections and lower respiratory tract infections.


    iGeneTech's Respiratory Syndrome Pathogenic Microorganism Identification Panels

    Based on its independently developed TargetSeq® liquid-phase hybridization capture sequencing technology, iGeneTech has launched over 40 identification Panels for common respiratory syndrome pathogenic microorganisms, with reference to multiple strain sequences included in the NCBI database.

    Among them, probes for 25 types of bacteria and fungi are designed following the principle of "intra-species conservation and inter-species specificity," while probes for 13 types of viruses adopt a full-length coverage design. A total of more than 150,000 probes have been developed, covering 38 common respiratory pathogens. These Panels can enhance the monitoring of respiratory pathogen spectra in populations, provide important support for epidemic trend assessment, early outbreak identification, and risk analysis, and meet the needs of routine prevention and control work of disease control and prevention departments.

     

    Table 1. Bacteria Involved in Diagnosis and Treatment of ABX Infectious Diseases

    Acinetobacter baumannii

    Actinomycete

    Aeromonas

    Bacillus

    Bacteroides fragilis

    Bacteroides

    Bartonella

    Bordetella

    Borrelia

    Brucella

    Burkholderia cepacia complex

    Burkholderia mallei

    Campylobacter

    Campylobacter jejuni

    Capnocytophaga canimorsus

    Chlamydia trachomatis

    Chlamydia pneumoniae

    Chlamydia psittaci

    Citrobacter

    Clostridium botulinum

    Clostridium difficile

    Clostridium

    Clostridium tetani

    Corynebacterium diphtheriae

    Coxiella burnetii

    Ehrlichia

    Eikenella corrodens

    Enterobacter

    Enterococcus

    Erysipelothrix rhusiopathiae

    Escherichia coli

    Francisella tularensis

    Haemophilus ducreyi

    Haemophilus influenzae

    Moraxella catarrhalis

    Klebsiella

     

    Lactobacillus

    Legionella

    Leptospira

    Listeria monocytogenes

    Morganella

    Mycobacterium abscessus

    Mycobacterium avium Complex

    Mycobacterium chelonae

    Mycobacterium fortuitum

    Mycobacterium kansasii

    Mycobacterium leprae

    Mycobacterium marinum

    Mycoplasma pneumoniae

    Neisseria gonorrhoeae

    Neisseria meningitidis

    Nocardia

    Pasteurella multocida

    Peptostreptococcus

    Plesiomonas

    Propionibacterium

    Proteus

    Providencia

    Pseudomonas aeruginosa

    Rhodococcus equi

    Rickettsia rickettsii

    Rickettsia

    Salmonella

    Shigella dysenteriae

    Shigella

    Staphylococcus

    Staphylococcus aureus

    Stenotrophomonas maltophilia

    Streptococcus moniliformis

    Streptococcus pneumoniae

    Streptococcus pyogenes

    Streptococcus

    Treponema pallidum

    Tropheryma whipplei

    Vibrio cholerae

    Vibrio

    Yersinia pestis

    Yersinia

     

    Table 2. Fungi Involved in Diagnosis and Treatment of ABX Infectious Diseases

    Aspergillus

    Blastomyces dermatitidis

    Candida albicans

    Candida

    Coccidioides immitis

    Cryptococcus neoformans

    Dermatophyte

    Fusarium

    Histoplasma capsulatum

    Scedosporium boydii

    Sporothrix schenckii


     

    Table 3. Viruses Involved in Diagnosis and Treatment of ABX Infectious Diseases 

    Mastadenovirus

    Cytomegalovirus

    Enterovirus

    Epstein-Barr virus

    Hantaviridae

    Hepatitis A virus

    Hepatitis B virus

    Hepacivirus hominis

    Herpes simplex virus

    human gammaherpesvirus 8

    Hepatitis D virus

    human Papillomavirus

    JC virus × BK virus

    Measles morbillivirus

    Molluscum contagiosum virus

    Mumps orthorubulavirus

    Norovirus

    Respirovirus

    Human parvovirus B19

    Lyssavirus

    Human respiratory syncytial virus

    Rhinovirus

    Rubella virus

    Zoster virus

    West Nile virus

    Human T- lymphotropic virus (HTLV)



     

    Experimental Workflow of Probe Capture for Respiratory Syndrome Identification

    1. Nucleic Acid Extraction (0.5 h)

    2. Library Preparation (2.5 h)

    3. Probe Capture (3 h)

    4. Sequencing (3 h)

    5. Data Analysis

    LibraryProbe Hybridization 0.5-1 h

    *Sequencing duration is calculated based on the GeneMind FASTASeq S series sequencer and SE100 sequencing strategy.

     

    Product Advantages

    1. Broad Sample Compatibility, No Pre-Cultivation Required

    Supports multiple raw sample types including sewage, human-derived, and environmental samples. Eliminates the need for pre-cultivation and host depletion steps, greatly simplifying the sample preprocessing workflow and significantly improving detection efficiency.

    2. Broad Strain Coverage, Complete and Reliable Data

    Based on efficient probe hybridization capture and enrichment technology, it enables accurate and unbiased identification and detection of sample genomes.

    3. Excellent Sensitivity for Capturing Weak Signals

    Addressing the core challenge of low-load infections, probe optimization achieves efficient binding and enrichment of target sequences. Even trace amounts of pathogen nucleic acids can be stably captured, laying a solid foundation for downstream high-sensitivity detection.

    4. Rapid and Efficient Hybridization

    Powered by TargetSeq® liquid-phase hybridization capture technology, the hybridization between libraries and probes takes only 0.5-1 hour. Combined with fast nucleic acid extraction, library preparation, and sequencing processes, it drastically shortens the detection cycle.

    Worry-Free End-to-End Detection

    The Respiratory Syndrome Identification Probe Kit has sufficient stock. It is paired with magnetic bead-based extraction kits, RNA pathogen library construction & capture kits, and DNA pathogen library construction & capture kits, enabling seamless connection from sample to data. It supports batch processing with automated liquid handling workstations and is compatible with multiple high-throughput sequencing platforms to meet the needs of various scenarios.

     

    Product Info

    Product Name

    Speci.

    Cat. No

    Respiratory Syndrome Identification Panel

    16 rxn

    PH2014801

    Magnetic Beads Based Pathogen DNA / RNA Co-Extraction Kit

    50 rxn

    E10021

    IGT® RNA Pathogen Microbial Library Prep & Capture KitIllumina

    16rxn

    C11371

    IGT® RNA Pathogen Microbial Library Prep & Capture KitMGI

    16 rxn

    C11441

    IGT-AS12 Automated Liquid Handling Workstation

    Configuration III

    Q91013


    References